241 related articles for article (PubMed ID: 17322412)
1. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
D'Annunzio V; Donato M; Erni L; Miksztowicz V; Buchholz B; Carrión CL; Schreier L; Wikinski R; Gelpi RJ; Berg G; Basso N
J Cardiovasc Pharmacol; 2009 Feb; 53(2):137-44. PubMed ID: 19188835
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Weinberg EO; Scherrer-Crosbie M; Picard MH; Nasseri BA; MacGillivray C; Gannon J; Lian Q; Bloch KD; Lee RT
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
5. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
6. Statins and the response to myocardial injury.
Scalia R
Am J Cardiovasc Drugs; 2005; 5(3):163-70. PubMed ID: 15901204
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart.
Wu N; Li W; Lv Y; Shu W; Jia D
Pharmazie; 2014 Sep; 69(9):704-8. PubMed ID: 25272944
[TBL] [Abstract][Full Text] [Related]
8. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.
Ozturk N; Yaras N; Ozmen A; Ozdemir S
J Bioenerg Biomembr; 2013 Aug; 45(4):343-52. PubMed ID: 23640692
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.
Burma O; Onat E; Uysal A; Ilhan N; Erol D; Ozcan M; Sahna E
Cardiovasc J Afr; 2014; 25(5):212-6. PubMed ID: 25629537
[TBL] [Abstract][Full Text] [Related]
10. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Birnbaum Y; Lin Y; Ye Y; Martinez JD; Huang MH; Lui CY; Perez-Polo JR; Uretsky BF
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2891-7. PubMed ID: 17277020
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
Ikeda Y; Young LH; Lefer AM
J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
13. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Bulhak AA; Gourine AV; Gonon AT; Sjöquist PO; Valen G; Pernow J
Acta Physiol Scand; 2005 Feb; 183(2):151-9. PubMed ID: 15676056
[TBL] [Abstract][Full Text] [Related]
14. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Vilahur G; Casaní L; Peña E; Duran X; Juan-Babot O; Badimon L
Atherosclerosis; 2009 Sep; 206(1):95-101. PubMed ID: 19419716
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Satoh K; Takaguri A; Itagaki M; Kano S; Ichihara K
J Pharmacol Sci; 2008 Apr; 106(4):593-9. PubMed ID: 18403900
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats.
Hu X; Sun A; Xie X; Huang Z; Jia J; Yao R; Ge J
J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):162-76. PubMed ID: 23139358
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
Habibi J; Whaley-Connell A; Qazi MA; Hayden MR; Cooper SA; Tramontano A; Thyfault J; Stump C; Ferrario C; Muniyappa R; Sowers JR
Endocrinology; 2007 May; 148(5):2181-8. PubMed ID: 17317778
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein.
Naito Y; Katada K; Takagi T; Tsuboi H; Kuroda M; Handa O; Kokura S; Yoshida N; Ichikawa H; Yoshikawa T
World J Gastroenterol; 2006 Apr; 12(13):2024-30. PubMed ID: 16610051
[TBL] [Abstract][Full Text] [Related]
20. Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo.
Pagel PS; Krolikowski JG; Shim YH; Venkatapuram S; Kersten JR; Weihrauch D; Warltier DC; Pratt PF
Anesth Analg; 2007 Sep; 105(3):562-9. PubMed ID: 17717207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]